Atezolizumab associated with Bevacizumab in non-clear cell renal cell carcinoma and clear cell renal cell carcinoma with sarcomatoid differentiation


Non-clear cell renal cell carcinoma ( NccRCC ) and clear cell renal cell carcinoma with sarcomatoid differentiation ( sccRCC ) have historically been underrepresented in clinical trials.
Even with targeted therapy, most patients have inferior survival compared to clear cell renal cell carcinoma.
The combination of Atezolizumab ( Tecentriq ) and Bevacizumab ( Avastin ) has demonstrated safety and efficacy in clear cell renal cell carcinoma.

In this multicenter, phase II, open-label, single arm trial researchers have evaluated the efficacy of Atezolizumab and Bevacizumab in patients with nccRCC and sccRCC with more than 20% sarcomatoid differentiation.

Eligible patients had an ECOG performance status of 0-2 and may have received prior therapy. Prior PD-1/PD-L1 therapy was not allowed.

Patients underwent a mandatory baseline biopsy and subsequently received Atezolizumab 120 mg and Bevacizumab 15 mg/kg intravenously every 3 weeks.
Patients remained on therapy until radiographic progression, unacceptable adverse events, or withdrawal.
The primary end point was overall response rate ( ORR ) as determined by RECIST version 1.1.

65 patients were enrolled of whom 52 had greater than or to 1 response assessment and were included in this analysis.
36 patients had nccRCC ( papillary n=14, chromophobe n=8, unclassified RCC n=3, collecting duct n=3, translocation n=3, other n=5 ), and 16 patients had sccRCC.
17 patients received prior systemic therapy, 16 of whom had nccRCC.

The ORR was 31% in the overall cohort.

10 patients ( 19% ) developed grade 3 treatment-related adverse events, half of which were immune-related.
There were no grade 4-5 adverse events.

In this study, researchers have shown that therapy with Atezolizumab and Bevacizumab was safe and demonstrated anti-tumor activity in nccRCC and sccRCC. ( Xagena )

Source: Genitourinary Cancers Symposium, 2019

XagenaMedicine_2019



Indietro

Altri articoli

Human papillomavirus ( HPV ) causes nearly all cervical cancers and some cancers of the vagina, vulva, penis, anus, and...


In an extensive data mining analysis of British medical records, researchers at the Johns Hopkins Kimmel Cancer Center have concluded...


The European Commission has approved Tecentriq ( Atezolizumab ) plus chemotherapy ( Abraxane [ Paclitaxel protein-bound particles for injectable suspension...


The Food and Drug Administration ( FDA ) has approved Nubeqa ( Darolutamide ) for non-metastatic castration-resistant prostate cancer. Approval was...


The phase 3 KEYNOTE-522 trial investigating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in combination with chemotherapy has met one...


The first prospective, longitudinal study investigating treatment of chronic hepatitis C with direct-acting antivirals finds that the treatment is associated...


Hyperprogressive disease ( HPD ) is a paradoxical boost in tumour growth described in a subset of cancer patients treated...


The first-line treatment with Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in combination with chemotherapy has demonstrated improvements in overall...


A subset of patients treated with immune checkpoint inhibitors experience an accelerated tumor growth rate ( TGR ) in comparison...


Diabetes confers a greater excess risk of heart failure in women than men, according to new research in Diabetologia, the...